No deal has been announced, but the money may already be lined up. That is the contention of Reuters, which earlier this week cited sources as saying Watson Pharmaceuticals ($WPI) has Actavis in its sights. Today, the news service says banks are falling all over themselves to provide financing for said deal, according to sources. It could take $6 billion to combine the two generics manufacturers, and that certainly would be a significant transaction. Bank of America Merrill Lynch, which has a relationship with Watson, is the front-runner to lead a deal that will probably involve a $2 billion term loan and a $4 billion bridge-to-bond arrangement, the news service says. Story | More